Insulet Co. (NASDAQ:PODD) Shares Bought by Norinchukin Bank The

Norinchukin Bank The raised its stake in shares of Insulet Co. (NASDAQ:PODD) by 9.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,136 shares of the medical instruments supplier’s stock after buying an additional 263 shares during the period. Norinchukin Bank The’s holdings in Insulet were worth $819,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S grew its holdings in Insulet by 227.9% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 8,674 shares of the medical instruments supplier’s stock worth $2,265,000 after acquiring an additional 6,029 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Insulet by 42.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 289,507 shares of the medical instruments supplier’s stock worth $75,588,000 after purchasing an additional 86,505 shares during the period. First Trust Advisors LP increased its holdings in shares of Insulet by 71.0% during the 4th quarter. First Trust Advisors LP now owns 144,913 shares of the medical instruments supplier’s stock valued at $37,832,000 after purchasing an additional 60,187 shares in the last quarter. Commerce Bank lifted its stake in shares of Insulet by 3.4% in the 4th quarter. Commerce Bank now owns 3,887 shares of the medical instruments supplier’s stock valued at $1,015,000 after purchasing an additional 128 shares during the period. Finally, Alpha DNA Investment Management LLC purchased a new stake in Insulet during the fourth quarter worth $725,000.

Insider Activity

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Performance

NASDAQ PODD opened at $238.57 on Tuesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock’s fifty day moving average is $262.47 and its two-hundred day moving average is $261.27. The firm has a market capitalization of $16.75 billion, a P/E ratio of 41.20, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. On average, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Piper Sandler lifted their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group lifted their price target on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company increased their price target on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Citigroup boosted their price objective on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.